Since AbbVie's founding CEO handed the company to a finance-background successor in 2024, it has announced a guidance “raise” nearly every quarter while its actual full-year EPS target kept falling — the gap driven by the cost of an ongoing acquisition spree, not a weakening base business.
The story
Late 2023: "performing exceptionally well"
In the second half of 2023, founding CEO Rick Gonzalez was telling a confident story: AbbVie was successfully absorbing what he called the largest loss-of-exclusivity event in the industry's history. On the Q3 2023 earnings call, he said "AbbVie continues to perform exceptionally well," promising that Skyrizi and Rinvoq combined would exceed Humira's peak revenue by 2027 — and raised full-year guidance for the third time that year.
The turning point: a new CEO, and a new strategy of buying growth
Then, in early 2024, something fundamental changed. On the Q1 2024 call, Gonzalez announced he would step down as CEO on July 1 after more than 11 years leading the company since its 2013 spinoff from Abbott. His successor: Robert Michael, AbbVie's CFO since 2019 — a finance-background executive, not an operator. In the very same quarter that leadership transition was announced, AbbVie began a buying spree, kicking off with the ImmunoGen and Cerevel acquisitions (over $18 billion combined). And starting that quarter, something odd began happening: AbbVie kept announcing it was "raising guidance" every quarter, while the actual full-year adjusted EPS number kept falling — from a $11.15 midpoint in February, to $11.23 in May, to $10.81 in August, to $10.92 in November. By year-end, the company missed even the $11 "floor" Gonzalez had explicitly promised in October 2023, finishing 2024 at an actual adjusted EPS of $10.12.
The pattern repeats: raise the headline, lower the number
Rather than hide the gap, AbbVie's response was to split the story into two separate narratives. The same pattern repeated almost exactly in 2025: guidance started at a $12.22 midpoint in January, was "raised" three separate times, yet the actual figures fell each time — $12.19, then $11.98, then $10.63 — before landing at an actual $10.00, an 18% miss from the original number. On the Q2 2026 call, CFO Scott Reents explained the mechanism directly: "this adjustment reflects a $0.10 improvement in our base business outlook, offset by a newly incorporated $0.14 of expected dilution related to the planned Aliada acquisition — which more than offsets our actual outperformance." In other words, "the core business beats expectations every quarter" and "we're spending more than that on new acquisitions" have become two sentences that always travel together in this company's communications.
Where it stands now
On the Q3 2025 call, Michael said there were "no major loss-of-exclusivity events on the horizon," giving the company "a clear growth runway into the 2030s," and the Q4 2025 call disclosed AbbVie had spent more than $5 billion on business development over five years, continuing to acquire early-stage biotechs like Capstan Therapeutics and Aliada Therapeutics. A new risk factor appeared for the first time in the FY2025 10-K: tariffs and trade policy. In January 2026, AbbVie signed a voluntary agreement with the U.S. government trading tariff exemptions for a delay on future drug-price controls — a type of risk that didn't exist in prior filings at all.
Guidance vs. actual results
| Fiscal year | Initial guidance (midpoint) | Guidance path during the year | Actual | Result |
|---|---|---|---|---|
| FY2024 | $11.15 ("floor of $11" stated separately, Oct. 2023) | $11.23 → $10.81 → $10.92 | $10.12 | Missed by -$1.03 (-9.2%), below the stated floor |
| FY2025 | $12.22 | $12.19 → $11.98 → $10.63 | $10.00 | Missed by -$2.22 (-18.2%) |
| FY2026 (in progress) | $14.47 | $14.18 → $13.97 → ... | Not yet final | Same pattern continuing |
Source: earnings-call guidance statements, Q3 FY2023 through Q2 FY2026.
Quarter to quarter, AbbVie's own results have consistently beaten the guidance midpoint by a small margin ($0.06–$0.14) — a textbook conservative-guidance pattern. The problem shows up at the full-year level: each year's headline "guidance raise" has coincided with a falling annual number, driven by amortization and milestone costs from new acquisitions (ImmunoGen and Cerevel, then Capstan and Aliada). No formal guidance withdrawal has occurred, but three consecutive years of widening gaps between the initial promise and the actual result is itself a significant warning sign.
Timeline
- H2 2023Guidance raised three times on Skyrizi/Rinvoq strength; CEO Gonzalez calls $11 EPS a "floor" for 2024.
- Q1 2024Gonzalez announces retirement after 11+ years as founding CEO, effective July 1; CFO Robert Michael named successor. ImmunoGen and Cerevel acquisitions announced the same quarter.
- All of 2024"Guidance raised" announced every quarter, while the actual EPS figure keeps falling; year ends at $10.12, missing the stated $11 floor.
- July 2024Robert Michael formally becomes CEO; Gonzalez moves to board chair.
- 2025Same pattern repeats: three guidance "raises" during the year, actual result 18% below the initial number. Capstan Therapeutics acquired; Michael adds board chair role in July.
- FY2025 10-K (Feb. 2026)New tariff and trade-policy risk factor appears for the first time; patent-cliff risk language broadens from naming Humira specifically to covering "any of our products."
- Q1–Q2 2026Aliada Therapeutics acquisition announced; voluntary tariff-exemption agreement signed with the U.S. government. Same guidance pattern confirmed for a third consecutive year.
Our read
The core business here genuinely holds up — AbbVie hasn't missed its own quarterly guidance once across the twelve quarters reviewed. What's changed is what "raising guidance" means: the headline announcement bundles a real beat in the base business with a growing drag from new acquisition costs, and the second number has been outrunning the first for three straight years. An investor following this stock needs to look past the "guidance raised" headline each quarter and check the acquisition-dilution figure buried inside it to know whether the underlying business is actually improving.
What we still don't know
- How much of the 2024–2025 guidance misses are purely acquisition accounting versus a genuine slowdown in the base business can't be fully separated without reviewing each deal's individual amortization schedule.
- Whether AbbVie will actually bring net-debt-to-EBITDA back to 2x within two to three years of the Aliada deal, as repeatedly stated, is unconfirmed — and whether it met that same promise after the 2021 Allergan acquisition is outside the scope of this analysis.
- How persistently analysts have pressed management on the "raise guidance, lower the number" gap in Q&A wasn't fully assessed here; this piece focused on prepared remarks.
Frequently asked questions
Why does AbbVie's guidance keep falling even after being “raised”?
Each quarterly “raise” combines a genuine beat in the core business with a growing drag from acquisition-related amortization and milestone costs (from deals like ImmunoGen, Cerevel, Capstan, and Aliada) — and the acquisition drag has outpaced the underlying beat for three straight years.
Has AbbVie ever missed its own quarterly guidance?
No — across the twelve quarters reviewed, AbbVie beat its own quarterly guidance every time. The gap shows up only at the full-year level, where the initial annual EPS promise has missed by 9% (FY2024) and 18% (FY2025).
What sources does this analysis draw from?
This piece is built from AbbVie's 10-K filings for fiscal years 2023 through 2025 and twelve quarters of earnings-call transcripts spanning Q3 FY2023 through Q2 FY2026.